BofA lowered the firm’s price target on Surgery Partners (SGRY) to $17.50 from $24 and keeps a Buy rating on the shares. Q4 adjusted EBITDA missed by 7% on much lower margins and Surgery guided to 2026 EBITDA 11% below consensus on lower margins and a lack of deals, notes the analyst, who is cutting estimates after the “disappointing” report and outlook.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Morning Movers: Pinterest jumps following $1B investment from Elliot
- Surgery Partners price target lowered to $14 from $18 at Barclays
- Closing Bell Movers: MongoDB down over 20% after soft Q1 guidance
- Surgery Partners Announces Share Buyback and 2026 Outlook
- Surgery Partners sees FY26 revenue $3.35B-$3.45B, consensus $3.56B